Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study

Conclusions Subjects randomised to receive ONO-9054 were more likely to achieve a greater per cent reduction in IOP and were more likely to achieve target IOPs than those receiving Xalatan. The effects of ONO-9054 in reducing IOP appear to persist longer than those of Xalatan. Trial registration number NCT02083289, Results.

http://bjo.bmj.com/cgi/content/short/101/6/796?rss=1

Source: British Journal of Ophthalmology - May 30, 2017 Category: Opthalmology Authors: Miller Ellis, E., Berlin, M. S., Ward, C. L., Sharpe, J. A., Jamil, A., Harris, A. Tags: Angle, Intraocular pressure, Open access, Glaucoma Original articles - Clinical science Source Type: research